

# **Ugro Capital Limited**

Reaches the \$1Bn AUM club

In Q3 FY24, Ugro Capital Ltd (Ugro) recorded a strong growth in total income, driven by Income on Co-Lending which grew by 18% on a QoQ and 78% on a YoY basis to Rs. 764 Mn. Further, Interest Income grew by 6% on a QoQ and 37% on a YoY basis to Rs. 1828 Mn. PPOP increased from Rs. 389 Mn to Rs. 761 Mn, showing a robust growth of 95% on a YoY basis. AUM has increased to Rs. 84 Bn, growing by 10% on a QoQ and 64% on a YoY basis.

### **Strong Loan Origination**

Ugro continues to deliver strong net loan origination which amounted to Rs. 281 Mn in Q3 FY24, growing by 33% on a YoY basis. This was driven primarily by the Partnerships & Alliances, Machinery Loan and Prime Unsecured segments which grew by 78%, 68% and 52% respectively on a YoY basis. The Company has seen business rebound in the post pandemic times as evident in the increase in total loans per customer from Rs. ~4-4.5 Mn in CY19-21 to Rs. ~7-9Mn CY22 onwards. Such persisting growth and a huge market opportunity (Rs. 92 Trn MSME Credit Gap) shall further solidify Ugro's market position.

### **Operating Leverage continues to unfold**

Underpinned by Ugro's early investments in operating expenses and infrastructure, the Company continues to witness robust growth in both top line and bottom line performance. In 9M FY24, Ugro achieved a notable 64% increase in AUM on a YoY basis, alongside a threefold rise in PAT from Rs. 257 Mn to Rs. 867 Mn, propelled by a formidable operating leverage. Further, over the past eight quarters, the Company's PBT has consistently climbed from Rs. 50 Mn in Q3 FY22 to an impressive Rs. 460 Mn in Q3 FY24. This upward trajectory correlates with the tripling of AUM, rising from Rs. 25 Bn to Rs. 84 Bn, and can be attributed to strategic early investments in a diversified distribution channel, robust partnerships with leading banks and major NBFCs for co-lending and co-origination, investments in the GRO score and sustained support from its balance sheet liability providers, demonstrating the seamless integration of strategic foresight and operational leverage.

### View & valuation

We have revised our estimates and maintain a BUY rating on Ugro Capital Ltd with a target price of Rs. 323 (1.7x FY25E BV).

## 25th January 2024

## BUY

CMP Rs. 280 TARGET Rs. 323 (15%)


### **Company Data**

Bloomberg Code	UGRO IN
MCAP (Rs. Mn)	25,928
O/S Shares (Mn)	92.8
52w High/Low	320 / 144
Face Value (Rs.)	10
Liquidity (3M) (Rs. Mn)	72

### **Shareholding Pattern %**

	Dec 23	Sept 23	Jun 23
Promoters	2.24	2.24	2.19
FIIs	19.77	19.20	21.99
DIIs	4.46	5.81	5.46
Non- Institutional	73.53	72.74	70.36

### **Ugro Capital vs Nifty**



Source: Keynote Capitals Ltd.

#### **Key Financial Data**

Key Fillalicia	ii Data		
(Rs Bn)	FY23	FY24E	FY25E
NII	3.91	6.02	8.39
PPOP	1.41	2.77	4.34
Net Profit	0.40	1.26	2.33
<b>Total Assets</b>	43.06	67.60	92.74
ROA (%)	1.1%	2.3%	2.9%

Source: Company, Keynote Capitals Ltd. estimates

**Chirag Maroo,** Research Analyst Chirag@keynotecapitals.net






## Q3 FY24 Result Update

### Result Highlight (Rs. Mn)

Particulars	Q3 FY24	Q3 FY23	Change % (Y-o-Y)	Q2 FY24	Change % (Q-o-Q)	9M FY24	9M FY23	Change % (Y-o-Y)	FY23
Interest Income	1,828	1,331	37%	1,719	6%	5,162	3,418	51%	4,829
Income on Co-Lending /									
Direct Assignment	764	429	78%	648	18%	1,851	917	102%	1,541
Other Income	201	136	48%	170	18%	500	331	51%	468
Total Income	2,793	1,896	47%	2,536	10%	7,513	4,666	61%	6,838
Interest Expenses	1,167	816	43%	1,054	11%	3,148	2,029	55%	2,933
Net Total Income	1,626	1,080	51%	1,482	10%	4,365	2,637	66%	3,905
Employee Benefit Expense	485	405	20%	460	5%	1,314	1,006	31%	1,407
Other Expenses	380	286	33%	368	3%	1,070	736	45%	1,091
PPOP	761	389	95%	654	16%	1,980	895	121%	1,406
Credit Cost	297	167	78%	246	21%	752	393	91%	568
PBT	464	222	109%	408	14%	1,228	502	145%	838
Tax Expense	138	91	52%	119	16%	362	244	48%	441
PAT	325	131	148%	289	13%	867	257	237%	398


Source: Company, Keynote Capitals Ltd.

### **Quarterly Business Progression**




Source: Company, Keynote Capitals Ltd.










Source: Company, Keynote Capitals Ltd.

Loan Types (%)



Source: Company, Keynote Capitals Ltd.


### **Q3 FY24 Conference Call Takeaways**

- The business activity has seen strong rebound since Q3 CY21 wherein 77% of MSMEs in UGRO's target segment experienced business resumption and in the year after that, 68% of MSMEs showed 10% growth in turnover on a YoY basis. This led to an increase in credit sanctioned per customer highlighting the resilience of the sector.
- The increase in GNPA by 10/30 bps on a QoQ/YoY basis is attributed to the maturation of the portfolio and the management does not see it as weakening of credit quality, backed by the stable collection efficiency data over time at ~97% (excluding overdue). The GNPA of Prime Unsecured segment which is currently at 3.6% is within the lifetime target range of 4.5-5%. Beyond the NPAs, the corresponding credit costs are also aligned with the strategic target range of annualized 1.5-2%.



## **Ugro Capital Limited | Quarterly Update**

- The Company expects, the steady-state GNPA for Micro Enterprise Loan segment to be ~2.5-3%, where the corresponding credit cost would be in the range of 0.75-1%. The GNPAs for the retailer finance segment on a steady state basis would be 2-2.5%. For the Machinery Loan segment, GNPAs are expected in the range of 0.75-1% with corresponding credit costs at 0.2-0.3%.
- The Company expects to go live with 75 new physical branches over the next
  two quarters of which 30 will go live in the current quarter, which will take
  12-15 months to breakeven. The relative increase in operating expenses of
  the physical infrastructure has very limited impact on overall profitability.
  Currently, the Company has 75 matured branches which are contributing Rs.
  750 Mn per month and expects the new branches to perform similarly once
  they breakeven.
- Net loan origination in the Micro Enterprise Loan segment was lower on a QoQ basis due to the moderation of the non-collateralized loans within the segment because it was cannibalizing the secured loan products as the customers tended to not offer a collateral when that option was available.
- 95% to 98% of Ugro's co-origination was done with the larger NBFCs, whereby Ugro also provided some kind of first loss cover. However, with the introduction of the credit guarantee scheme for co-lending, coupled with the recent adjustment in the interest rate cap from 18% to 21%, has led to co-origination business transition towards the banks, leading to increase in the co-lending income.
- The net origination in the Prime Secured segment has experienced a decline over the last few quarters because of the decision to scale down the affordable LAP part of the segment. That business was conducted on the periphery of the large cities, where the collateral, may not have been considered prime and the Company saw some resistance by some of the colending partners to onboard this collateral prompting a scaling down of the business.
- Though there are some transactions on the debt side and the Company has an approval to raise Rs. 5 Bn, the Company is currently well capitalized and the exact timing of the fund raise is yet to be determined.





### **Financial Statement Analysis**

### **Income Statement**

Particulars	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	2,721	4,829	7,126	9,976	12,869
Income from Co-Lending/DA	269	1,541	2,746	3,982	5,177
Other Income	131	468	751	1,009	1,250
Total Income	3,121	6,838	10,623	14,967	19,296
Finance cost	1,373	2,933	4,602	6,582	8,721
Net Total Income	1,749	3,905	6,021	8,385	10,575
Employee benefits expense	729	1,407	1,840	2,021	2,203
Depreciation, amortisation and					
impairment	123	176	296	400	450
Other expenses	399	916	1,116	1,629	1,956
PPOP	498	1,406	2,769	4,335	5,966
Impairment on financial instruments	296	568	1,025	1,225	1,500
PBT	202	838	1,744	3,110	4,466
Tax expense	56	440	488	778	1,116
PAT	146	398	1,256	2,333	3,349


### **Balance Sheet**

Particulars (Rs in Mn)	FY22	FY23	FY24E	FY25E	FY26E
Cash and Bank balances	1,884	2,118	4,545	5,282	6,901
Loans	24,505	38,064	59,380	83,132	1,07,240
Fixed Assets	616	992	1,289	1,504	1,956
Investments	694	601	781	938	1,224
Other assets	844	1,281	1,601	1,889	2,456
Total Assets	28,542	43,056	67,596	92,745	1,19,777
Equity share capital	706	693	928	928	928
Other equity	8,960	9,147	13,436	15,768	19,118
Incremental Equity	-			2,000	2,000
Net worth	9,666	9,840	14,364	18,696	22,046
Borrowings	18,018	31,489	51,327	71,858	95,212
Other liabilities	858	1,727	1,905	2,191	2,519
Total Liabilities and Equity	28,542	43,056	67,596	92,745	1,19,777

Source: Company, Keynote Capitals Ltd.

### **KEYNOTE Rating History**

Date	Rating	Market Price at Recommendation	Upside/Downside
17 <sup>th</sup> February 2023	BUY	154	28%
17 <sup>th</sup> May 2023	NEUTRAL	189	8%
3 <sup>rd</sup> August 2023	виу	269	15%
27 <sup>th</sup> October 2023	виу	304	14%
25 <sup>th</sup> January 2024	виу	280	15%





### **Rating Methodology**

Rating	Criteria		
BUY	Expected positive return of > 10% over 1-year horizon		
NEUTRAL	Expected positive return of > 0% to < 10% over 1-year horizon		
REDUCE	Expected return of < 0% to -10% over 1-year horizon		
SELL	Expected to fall by >10% over 1-year horizon		
NOT RATED (NR)/UNDER REVIEW (UR)/COVERAGE SUSPENDED (CS)	Not covered by Keynote Capitals Ltd/Rating & Fair value under Review/Keynote Capitals Ltd has suspended coverage		

### **Disclosures and Disclaimers**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Keynote Capitals Ltd. (KCL) is a SEBI Registered Research Analyst having registration no. INH000007997. KCL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. Details of associate entities of Keynote Capitals Limited are available on the website at <a href="https://www.keynotecapitals.com/associate-entities/">https://www.keynotecapitals.com/associate-entities/</a>

KCL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

KCL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that KCL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Details of pending Enquiry Proceedings of KCL are available on the website at <a href="https://www.keynotecapitals.com/pending-enquiry-proceedings/">https://www.keynotecapitals.com/pending-enquiry-proceedings/</a>


A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of KCL or its associates maintains arm's length distance with Research Team as all the activities are segregated from KCL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL & its group companies to registration or licensing requirements within such jurisdictions. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

### Specific Disclosure of Interest statement for subjected Scrip in this document:

Financial Interest of Research Entity [KCL] and its associates; Research Analyst and its Relatives	NO
Any other material conflict of interest at the time of publishing the research report by Research Entity [KCL] and its associates;	NO
Research Analyst and its Relatives  Receipt of compensation by KCL or its Associate Companies from the subject company covered for in the last twelve months;  Managing/co-managing public offering of securities in the last twelve months; Receipt of compensation towards Investment banking/merchant banking/brokerage services in the last twelve months; Products or services other than those above in connection with research report in the last twelve months; Compensation or other benefits from the subject company or third party in connection with the research report in the last twelve months.	NO
Whether covering analyst has served as an officer, director or employee of the subject company covered	NO
Whether the KCL and its associates has been engaged in market making activity of the Subject Company	NO
Whether the Research Entity [KCL] and its associates; Research Analyst and its Relatives, have actual/beneficial ownership of 1% or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance.	NO





### The associates of KCL may have:

- financial interest in the subject company
- -actual/beneficial ownership of 1% or more securities in the subject company
- -received compensation/other benefits from the subject company in the past 12 months
- -other potential conflict of interests with respect to any recommendation and other related information and opinions.; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- -acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- -be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- -received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of KCL has not received any compensation or other benefits from third party in connection with the research report.

Above disclosures includes beneficial holdings lying in demat account of KCL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of KCL for other purposes (i.e. holding client securities, collaterals, error trades etc.). KCL also earns DP income from clients which are not considered in above disclosures.

### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### **Terms & Conditions:**

This report has been prepared by KCL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KCL. The report is based on the facts, figures and information that are believed to be true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KCL will not treat recipients as customers by virtue of their receiving this report

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative product as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. KCL, its associates, their directors and the employees may from time to time, effect or have affected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. KCL, its associates, their directors and the employees may from time to time invest in any discretionary PMS/AIF Fund and those respective PMS/AIF Funds may affect or have effected any transaction in for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of KCL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL to any registration or licensing requirement within such jurisdiction.





The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt KCL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold KCL or any of its affiliates or employees responsible for any such misuse and further agrees to hold KCL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

### Keynote Capitals Limited (CIN: U67120MH1995PLC088172)

Compliance Officer: Mr. Jairaj Nair; Tel: 022-68266000; email id: jairaj@keynoteindia.net

Registered Office: 9th Floor, The Ruby, Senapati Bapat Marg, Dadar West, Mumbai – 400028, Maharashtra. Tel: 022 – 68266000.

SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD): INZ000241530; DP: CDSL- IN-DP-238-2016; Research Analyst: INH000007997

For any complaints email at kcl@keynoteindia.net

General Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on <a href="https://www.keynotecapitals.com">www.keynotecapitals.com</a>; Investment in securities market are subject to market risks, read all the related documents carefully before investing.